Four months after failing in a mid-stage trial for Parkinson's disease, Sanofi's venglustat, once seen as a key candidate in its pipeline, has been discontinued as a treatment for an inherited condition that affects kidney function after a late-stage miss.
The French drugmaker has revealed that a pivotal Phase II/III study of venglustat in autosomal dominant polycystic kidney disease (ADPKD)...








